The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
what I'm trying to get at is Matt isn't the first on the board insinuate that its the 'placebo' they are short of on the Activ-2 trial, which I believe to be incorrect.
If they were to use the same placebo solution across all 7 current Activ-2 trials, and the same statement around 'limited supply' has not been made on the other drugs Activ-2 entry's (Which to my mind it hasn't) we can near categorically state that there has been a limited supply of our 'investigational agent' (SNG001).
And separately given your professional experience have you ever seen a clinical trial have supply issues for a placebo?
*the sp to be 20p lower
Don't want to be negative but I am expecting that someone will open short positions this week in sng.
The 90 day follow up will be the week starting on the 19th.
And it will take some time to put together the results.
My thought is that given how the chart look atm we could see tye share trading below the 200ma for some time.
Which means higher volatility lower SP and panick selling.
I am in profit but can't afford the so the be 20 lower again.
GL LTH
They take into account most placebos for the final decision regardless of treatment so what?
@Scinv - would all of the placebo's on Activ-2 be the same? regardless of delivery method?
https://clinicaltrials.gov/ct2/show/NCT04518410?term=ACTIV-2&draw=2
Matt activ people say so themselves. It has been discussed here as well and you have seen it. Maybe that attitude is OK in your trade but in the investment world this is filth. Do you really don't know where this comes from?
@Matt, the updated Activ-2 protocol was released on 31st March 21 (Dated 22nd Feb 21) stating the same line 'Participation in phase II evaluations of this agent will be restricted to select US sites, due to limited investigational agent/placebo supply.'
The "we know it works" doesn't stand from a regulatory point of view at the time it was made.
Like you said we don't know what happened but we DO know that they did have support, the government was interested and helping and were initially included in the Recovery etc but shortly after phase 2 results all of a sudden this was a £2.5K treatment, RM wanted to go alone and that gov was not convinced smg could produce significant quantities. Turns out, months later and even at least at the end of February this year, sng did not have enough juice to satisfy demand for the modestly sized activ 2 trial.
All imo of course.
What is frustrating for me is the time this is taking. Of course SNG001 needs to be proven to be safe and efficacious. However, if it had been a treatment found by large pharma or a discovery from Oxbridge or a company who has 'friends in the govt.', this treatment would have had EUA before Christmas and would be in widespread use right now. Deals could (should) have been done to give access to poorer countries so they can start to tackle the pandemic in their countries. Lives would be saved across the globe. I guess us mere mortals will never know the truth. Perhaps govts. are moving as fast as they can to get this treatment out there. Perhaps there are no vested interests getting in the way. Perhaps everything that could be done is being done. However, there is a part of me that is saying someone or something is the cause for this taking so long, (unnecessarily long). As far as I am concerned it has been 'smelly' for quite a while. I really hope I am wrong and there is a touch of paranoia in my musings. It seems Synairgen are having to tick every box (and more), dot every 'i' (and more),cross every 't' (and more) despite the weight of evidence from many years of safe interferon use for other conditions. We have risked new vaccines and hoped they would be safe. Why not risk a proven safe therapy that we know works. The world is in a mess and we need this therapy now. Sunday morning rant over and I have probably mis-read things totally.